BioNexus Gene Lab Corp Common stock Cash Flow Quality Index
BioNexus Gene Lab Corp Common stock cash flow quality index. BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow Quality Index of -3.38x as of June 2024. Operating cash flow of $-672.27K is below net income of $199.10K, suggesting accrual-heavy earnings not yet converted to cash. See BioNexus Gene Lab Corp Common stock (BGLC) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of BioNexus Gene Lab Corp Common stock (2018–2021)
Cash flow quality index of BioNexus Gene Lab Corp Common stock from 2018 to 2021. Historical Cash Flow Quality Index for BioNexus Gene Lab Corp Common stock across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore debt repayment capacity of BioNexus Gene Lab Corp Common stock to assess how comfortably operating cash covers total debt obligations.
BioNexus Gene Lab Corp Common stock Cash Flow Quality Index by Year (2018–2021)
BioNexus Gene Lab Corp Common stock cash flow quality index by year from 2018 to 2021. Year-by-year earnings quality comparison for BioNexus Gene Lab Corp Common stock. For the full cash flow conversion analysis, see BioNexus Gene Lab Corp Common stock cash flow conversion.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 0.01x | $9.16K | $751.57K | ▼ -97.6% |
| 2020 | 0.51x | $552.68K | $1.09 Million | ▲ +104.9% |
| 2018 | -10.36x | $-274.08K | $26.45K | — |